GlassScriptPhysician profile
Festus O Ebonka
NPI 1932241007
$2,149.59
in general payments reported to CMS, 2019-2025
16 companies · $475 in 2025
The $475 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $338 · 2022: $473 · 2023: $275 · 2024: $589 · 2025: $475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,339.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,338.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $543.60 | 2021-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $359.39 | 2021-2025 | Caplyta |
| Abbvie INC. | $319.03 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $203.41 | 2023-2025 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $183.41 | 2022-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Pfizer INC. | $113.24 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $107.47 | 2024-2025 | Airsupra, Breztri |
| Forte Bio-Pharma LLC | $93.15 | 2024-2025 | Prolate, Nalocet, Tanlor |
| Axsome Therapeutics, INC. | $41.81 | 2024 | Auvelity |
| Vanda Pharmaceuticals INC. | $41.06 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $38.26 | 2024 | Austedo Xr |
| Alkermes, INC. | $28.22 | 2025 | Aristada, Lybalvi |
| Orexo US, INC. | $19.91 | 2024 | Zubsolv |
| Janssen Pharmaceuticals, INC | $19.75 | 2022 | |
| Lundbeck LLC | $19.26 | 2023 | Rexulti |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $18.62 | 2025 | Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Festus Ebonka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.